Vaxart dosed the first patient in the 10,000-participant phase of its Phase 2b clinical trial for its oral COVID-19...

Fate Therapeutics will present clinical and preclinical data from its off-the-shelf cell therapy platform at the European Congress of...

ORIC Pharmaceuticals announced positive preliminary data from a Phase 1b trial of ORIC-944, a potential best-in-class PRC2 inhibitor, combined...

Taysha Gene Therapies announced positive clinical data from Part A of its REVEAL trials for TSHA-102 in Rett syndrome,...

Intrommune Therapeutics’ Oral Mucosal Immunotherapy (OMIT) platform, delivered via a specialized toothpaste containing peanut protein (INT301), has shown promising...

Vittoria Biotherapeutics is presenting its Phase 1 clinical trial results for VIPER-101, a gene-edited CAR-T therapy targeting CD5-positive T-cell...

SCYNEXIS has restarted patient dosing in its Phase 3 MARIO study of oral ibrexafungerp for invasive candidiasis after resolving...

Candel Therapeutics announced that its lead immunotherapy candidate, CAN-2409, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA...

Halberd Corporation, in collaboration with Athena Telemedicine Partners, reports positive clinical results for its patent-pending LDX compound in treating...

Syncromune’s Phase 1 clinical trial of SYNC-T Therapy SV-102 in patients with metastatic castration-resistant prostate cancer (mCRPC) showed an...